Advertisement|Remove ads.

Eli Lilly & Co. (LLY) on Monday announced a price cut for its blockbuster weight-loss drug, Zepbound, as it looks to match a similar price cut announced by rival Novo Nordisk AS (NVO).
Lilly announced that single-dose vials of Zepbound will now be available starting at $299 per month for the 2.5 milligram dose, down from $349. Patients can buy Zepbound at these prices through the company’s direct-to-consumer platform, LillyDirect.
This comes weeks after Novo Nordisk announced a similar price cut for its obesity and diabetes drugs, Wegovy and Ozempic, respectively.
Eli Lilly shares were down nearly 1% in Monday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory at the time of writing.
Get updates to this story developing directly on Stocktwits.
For updates and corrections, email newsroom[at]stocktwits[dot]com.